



Nyxoah announces appointment of new CEO Olivier Taelman

Mont-Saint-Guibert, Belgium – 28 November, 2019, Nyxoah S.A., a healthtech company developing neurostimulation-based therapeutic solutions for sleep related disorders, announced today the appointment of Olivier Taelman as new CEO of Nyxoah, following the resignation of Enrique Vega for personal reasons. Nyxoah's founder and chairman Robert Taub will continue to serve as executive chairman focused on business development and financing.

Olivier Taelman joined Nyxoah in July 2019 as Chief Operating and Commercial Officer with more than 20 years experience in commercial healthcare and general management roles. He spent 15 years within the field of neuromodulation including at Medtronic, Stryker and neuromodulation company Nevro where he was responsible for building the European business during the successful NASDAQ IPO. He holds an Executive MBA from Wharton and graduated in Biology from the University of Hasselt.

The board and the shareholders of Nyxoah would like to thank Enrique Vega for his contributions to the company including bringing Nyxoah from development stage to CE mark of its Genio® system.

– ENDS –

About Obstructive Sleep Apnea (OSA) and the Genio® system

OSA is the world's most common sleep disorder, affecting almost 1 billion people globally.¹ OSA makes a person stop breathing during sleep, while the airway repeatedly becomes partially (hypopnea) or totally (apnea) blocked, limiting the amount of air that reaches the lungs. OSA is associated with increased mortality risk and comorbidities, including cardiovascular diseases, depression and stroke. The current standard of care consists of Positive Airway Pressure (PAP) therapy, a treatment whereby air is pushed into the upper airway via a mask connected to a pump. Despite its proven efficacy, there are many limitations to this therapeutic option meaning compliance is a serious challenge.

The Genio® system is the world's first and only, battery-free, leadless and minimally invasive implanted neurostimulator that helps keep the upper airway open, allowing patients to

¹ Benjafield, Adam V et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. *Lancet Respir Med* 2019 Published Online July 9, 2019 [http://dx.doi.org/10.1016/S2213-2600\(19\)30198-5](http://dx.doi.org/10.1016/S2213-2600(19)30198-5)



breathe normally while sleeping. It offers a simple, convenient, safe and effective alternative to PAP, addressing the needs of patients seeking another treatment option.

About Nyxoah

Nyxoah is a healthtech company focused on the development of innovative, neurostimulation-based solutions and services for sleep related disorders. Nyxoah's lead technology is the Genio[®] system, the world's first and only, battery-free, leadless and minimally invasive implanted neurostimulator that treats the underlying cause of Obstructive Sleep Apnea (OSA), a market worth approximately \$10bn in the US alone. Following successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio[®] system received its European CE Mark in March 2019. The Company is currently conducting the Better Sleep study in Australia and New Zealand and a post- marketing ELiSA study in Europe to assess long-term safety and efficacy of the Genio[®] system. The US trial programme for FDA approval is in preparation.

For more information, please visit www.nyxoah.com.

Caution – CE marked since 2019. Investigational device in the USA. Limited by federal law to investigational use.